Bristol Myers Squibb stock may trade 48% below fair value on AI drug discovery push

Bristol-Myers Squibb's stock has attracted fresh attention following the company's expanded AI work with Nvidia and the establishment of a new San Diego R&D hub. These moves appear to have bolstered investor confidence, reflected in the 42.2% one-year return. However, the valuation picture remains mixed: a Discounted Cash Flow analysis points to meaningful undervaluation (48.1% discount to estimated intrinsic value), while the overall valuation checklist scores 4 out of 6, suggesting neither a clear bargain nor obvious overvaluation.

The DCF model underpinning the undervaluation thesis uses a latest twelve month free cash flow of about $12b as its starting point and assumes cash flows that decline before settling into a steady pattern, arriving at an intrinsic value of about $123 per share. The gap between this estimate and the current market price suggests potential upside — but only if the assumptions hold and the market has not already priced in the AI and R&D hub benefits. Regulatory uncertainty around partnered drugs and broader pipeline outcomes present a key risk to the durability of projected cash flows, meaning the 48.1% discount may not translate to realized returns if those headwinds materialize.